NIH awards $5M for heroin addiction, AIDS vaccine

The NIH is forking over $5 million over the course of 5 years to a Walter Reed Army Institute of Research scientist for advancing a dual vaccine to treat heroin addiction and protect against HIV infection. Gary Matyas is working on a vaccine that will focus on heroin abuse and the high risk of HIV infection in those who inject the drug with needles. The money comes specifically from the NIH's National Institute on Drug Abuse. Story

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.